Compounds > norethindrone acetate
Page last updated: 2024-11-07

norethindrone acetate and Obesity

norethindrone acetate has been researched along with Obesity in 5 studies

norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
" The ultra-low dose of ethinyl estradiol did not impact scheduled bleeding or intensity of bleeding, but we observed a slight decline in amenorrhea and slight increase in unscheduled bleeding in obese women compared with other BMI categories."5.22Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive. ( Archer, DF; Nakajima, ST; Pappadakis, J, 2016)
"norethindrone acetate, they were less likely to achieve menstrual suppression."1.91Norethindrone dosing for adequate menstrual suppression in adolescents. ( Compton, SD; Rager, TL; Rosen, MW; Winfrey, OK, 2023)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Rager, TL1
Compton, SD1
Winfrey, OK1
Rosen, MW1
Li, Y1
Chen, X1
Gong, X1
He, D1
Cheng, X1
Prabahar, K1
Hernández-Wolters, B1
Velu, P1
Du, W1
Nakajima, ST1
Pappadakis, J1
Archer, DF1
Demir, B1
Ozturkoglu, E1
Solaroglu, A1
Baskan, B1
Kandemir, O1
Karabulut, E1
Haberal, A1
Osmanağaoğlu, MA1
Osmanağaoğlu, S1
Osmanağaoğlu, T1
Okumuş, B1
Bozkaya, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open-Label Study of the Safety and Efficacy of a Low Dose Oral Contraceptive Containing Norethindrone Acetate and Ethinyl Estradiol[NCT00391807]Phase 31,683 participants (Actual)Interventional2006-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Median Duration of Withdrawal Bleeding, Cycle 12, MITT Population

(NCT00391807)
Timeframe: 12 cycles, 28 days each (336 days)

InterventionDays (Median)
Norethindrone/Ethinyl Estradiol3.85

Median Duration of Withdrawal Bleeding, Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionDays (Median)
Norethindrone/Ethinyl Estradiol3.93

Median Duration of Withdrawal Bleeding, Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionDays (Median)
Norethindrone/Ethinyl Estradiol3.99

Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 13, MITT Population

MITT Population (NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionBleeding/Spotting Days (Mean)
Norethindrone/Ethinyl Estradiol1.81

Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 2, MITT Population

MITT Population (NCT00391807)
Timeframe: 2 Cycles, 28 days each (56 days)

InterventionBleeding/Spotting Days (Mean)
Norethindrone/Ethinyl Estradiol3.21

Number of Intracyclic Bleeding (IB)/Spotting Days Cycle 6, MITT Population

MITT Population (NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionBleeding/Spotting Days (Mean)
Norethindrone/Ethinyl Estradiol2.00

Percentage of Subjects With Amenorrhea, Cycle 13, MITT Population

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol49.1

Percentage of Subjects With Amenorrhea, Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol30.7

Percentage of Subjects With Amenorrhea, Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol42.9

Percentage of Subjects With Withdrawal Bleeding (%), Cycle 13, MITT Population

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol22.4

Percentage of Subjects With Withdrawal Bleeding (%), Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol34.8

Percentage of Subjects With Withdrawal Bleeding (%), Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionPercentage of Participants (Number)
Norethindrone/Ethinyl Estradiol25.0

Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population,

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionPregnancy Rate (Number)
Norethindrone/Ethinyl Estradiol2.554

Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18-45, MITT Population

(NCT00391807)
Timeframe: 13 Cycles, 28 days each (1 year)

InterventionPregnancy Rate (Number)
Norethindrone/Ethinyl Estradiol2.167

Total Number of Bleeding Days Per Cycle, Cycle 13, MITT Population

(NCT00391807)
Timeframe: 13 cycles, 28 days each (1 year)

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol3.36

Total Number of Bleeding Days Per Cycle, Cycle 2, MITT Population

(NCT00391807)
Timeframe: 2 cycles, 28 days each (56 days)

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol4.57

Total Number of Bleeding Days Per Cycle, Cycle 6, MITT Population

(NCT00391807)
Timeframe: 6 cycles, 28 days each (168 days)

InterventionDays (Mean)
Norethindrone/Ethinyl Estradiol3.00

Reviews

1 review available for norethindrone acetate and Obesity

ArticleYear
The effect of 17beta-estradiol plus norethisterone acetate on anthropometric indices: A systematic review and meta-analysis of randomized controlled trials.
    European journal of obstetrics, gynecology, and reproductive biology, 2023, Volume: 287

    Topics: Body Weight; Dietary Supplements; Estradiol; Humans; Norethindrone Acetate; Obesity; Randomized Cont

2023

Trials

3 trials available for norethindrone acetate and Obesity

ArticleYear
Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive.
    Contraception, 2016, Volume: 93, Issue:1

    Topics: Adolescent; Adult; Amenorrhea; Body Mass Index; Contraceptives, Oral, Combined; Contraceptives, Oral

2016
The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal women.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2008, Volume: 24, Issue:6

    Topics: Blood Glucose; Carbohydrate Metabolism; Drug Therapy, Combination; Estradiol; Estrogen Replacement T

2008
Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
    Fertility and sterility, 2005, Volume: 84, Issue:2

    Topics: Adult; Aged; Blood Coagulation Factors; Blood Glucose; Body Mass Index; Bone Density; Contraceptives

2005

Other Studies

1 other study available for norethindrone acetate and Obesity

ArticleYear
Norethindrone dosing for adequate menstrual suppression in adolescents.
    Journal of pediatric endocrinology & metabolism : JPEM, 2023, Aug-28, Volume: 36, Issue:8

    Topics: Adolescent; Female; Humans; Menorrhagia; Norethindrone; Norethindrone Acetate; Obesity; Retrospectiv

2023